The Role of LRP in Amyloid Deposition in APP/PS1 Mice
About the Research Project
Program
Award Type
Pilot
Award Amount
$100,000
Active Dates
April 01, 2006 - September 30, 2009
Grant ID
A2006232
Goals
In this study, we will use transgenic mouse models to study the roles of LRP in modulating amyloid pathology. We will use a genetic system, called Cre/lox, to eliminate LRP expression in specific types of cells in the forebrains of mice and then assess how this manipulation has altered amyloid deposition.
Summary
There is substantial evidence to suggest that the deposition of beta-amyloid (small fragments of a protein called the amyloid precursor protein) triggers a cascade of events that ultimately causes the symptoms of Alzheimer’s disease. The life-long accumulation of amyloid peptide in the brain is determined by the rate of its generation versus clearance. A large number of studies have provided evidence that a protein called the low-density lipoprotein receptor-related protein (LRP) may play a pivotal role in regulating the production or clearance of amyloid peptides. In this study, we will use transgenic mouse models to study the roles of LRP in modulating amyloid pathology. We will use a genetic system, called Cre/lox, to eliminate LRP expression in specific types of cells in the forebrains of mice and then assess how this manipulation has altered amyloid deposition. It has been suggested that the binding of LRP to proteins involved in amyloid peptide production and clearance is the mechanism of action. If so, then it may be possible to identify drugs that modulate LRP binding to these proteins and thus influence its role in the formation of amyloid pathology.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD